Elemene liposomes for advanced or recurrent endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a drug called elemene liposomes, which may help treat advanced or recurrent endometrial cancer. It is given through an IV and as an oral solution. The study aims to see if this treatment is safe and effective for people who have not had chemotherapy or other cancer treatments recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have endometrial cancer that is stage III or IV, or it has come back after treatment.
- You have not had chemotherapy, immunotherapy, or radiation therapy within the last 6 months.
- You are generally able to care for yourself (ECOG score 0 or 1).
- Your blood counts and liver and kidney function are within acceptable ranges.
- You are not pregnant or breastfeeding.
- You have not had another type of cancer in the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial studies a combination of two oral drugs, elacestrant and everolimus, for advanced or recurrent endometrial cancer that is hormone receptor positive. The goal is to see if this combination can help shrink or slow the cancer.
This study tests whether adding another drug to the standard combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) can help treat advanced or recurrent endometrial cancer that has already progressed after platinum-based chemotherapy. If you qualify, you may have access to a new treatment option while helping doctors learn what works best.
This study tests whether adding a repurposed drug to the standard combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) can help treat advanced or recurrent endometrial cancer. It is for people whose cancer has returned or progressed after platinum chemotherapy and who are not suitable for curative surgery or radiation.
This trial tests a new medicine called QL1706 (a type of immunotherapy that helps your immune system fight cancer) combined with chemotherapy for women with advanced or recurrent endometrial cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help you live longer.
Hear when a new Endometrial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.